Resources

The early detection of clinical deterioration could be the next significant step in enhancing patient safety in general hospital wards. Most patients do not deteriorate suddenly; instead, their vital signs are often abnormal or trending towards an abnormal range hours before severe adverse events requiring rescue intervention and/or ICU transfer

Assessment of Physiological Signals from Photoplethysmography Sensors Compared to an Electrocardiogram Sensor: A Validation Study in Daily Life Overall, Corsano has better coverage for the processed R-R interval data as compared to Whoop. For Whoop, participants indicated a need to learn more before one could get going with the device and a need for more technical...

Survival from out-of-hospital cardiac arrest depends on immediate recognition and early cardiopulmonary resuscitation. Especially for unwitnessed cardiac arrest, survival chances are poor due to delays in receiving help. Automated cardiac arrest detection using wearables could facilitate early help.

Hypothalamic dysfunction may not only cause obesity, but also causes chronic fatigue and headaches, due to the many (neuro)-endocrine imbalances, such as temperature dysregulation, sodium changes and difficulties in regulating the hydrocortisone. With the watch we aim to better detect such imbalances so that we can prevent its consequences and improve quality of life.

The Synthetic hEalthcare dAta goveRnanCe Hub (SEARCH) aims to accelerate healthcare innovation by generating FAIRified synthetic data for use in AI/ML models

Corsano launched commercialization of its CardioWatch EU-MDR certified patient monitoring bracelet on cobas® pulse, a digitally enabled professional blood glucose management solution from Roche.

We are thrilled to announce that our CEO Peter Stas presented Corsano Health's innovative CardioWatch solution at HIMSS24 Startup Competition in Rome. This prestigious event showcases groundbreaking health tech and we are honored to be recognized among the best.

Corsano Health is announcing that its CardioWatch 287-2 System received FDA Clearance.

The occurrence of exacerbations has major effects on the health of people with chronic obstructive pulmonary disease (COPD). Monitoring devices that measure (vital) parameters hold promise for timely identification and treatment of exacerbations. Stakeholders' perspectives on the use of monitoring devices are of importance for the successful development and implementation of a device.

Collaborating researchers from Reinier de Graaf Hospital have validated the Corsano cuffless photoplethysmography-based wristband for measuring blood pressure according to the regulatory standards.

Collaborating researchers from Radboud University Medical Center, Erasmus MC, Reinier de Graaf Hospital, and Corsano Health have succeeded in reliably measuring whether a patient's circulation stops, as in the case of cardiac arrest.

Cisco and Corsano closely collaborated on the new Cisco Platform for In-Hospital Monitoring of patients. The revolutionary solution was showcased at Cisco Live 2024. The Corsano Bracelet streamed Vital Signs over BLE to Cisco’s latest router live at the Cisco Live event. We are proud to be Cisco’s Wearable Partner.

Radboud University Medical Center (RadboudUMC) has initiated a donation campaign to support the DETECT Cardiac Arrest project. This vital initiative aims to enhance the detection and response strategies for cardiac arrests, potentially saving numerous lives.

Pharmacovigilance, often referred to as "pharma vigilance," involves the activities related to the detection, assessment, understanding, and prevention of drug-related adverse effects.

Collaborating researchers from Radboud University Medical Center, Erasmus MC, Reinier de Graaf Hospital, and Corsano Health have succeeded in reliably measuring whether a patient's circulation stops, as in the case of cardiac arrest.

Students had Corsano CardioWatch 287-2 on their wrists, providing them with a practical opportunity to utilize medical-grade sensors. This allowed students to analyze their physiological responses throughout the course.

Hypertension increases cardiovascular risk. Measuring reliable blood pressure (sBP and dBP for systolic and diastolic BP) is challenging. A photoplethysmography (PPG)-based wristband with a custom BP algorithm could provide continuous BP.

This validation study showed that the Corsano 287 CardioWatch/Bracelet with PPG-technology can determine HR and RR-intervals with high accuracy in a cardiovascular patient population

The fully remote, investigator-initiated Smartphone and Corsano Health’s CardioWatch 287 wearable detected atrial arrhythmia in Older Adults Case finding study (Smart in OAC—AFNET 9) digitally enrolled participants ≥65 years without known atrial fibrillation

Chronic hypertension is a significant risk factor for cardiovascular diseases (CVD) [1]. However, obtaining reliable and reproducible cuff blood pressure (BP) measurements is challenging.

Automated cardiac arrest detection and alarming is a potential solution to shorten treatment delays after out-of-hospital cardiac arrest (OHCA). Especially for patients with unwitnessed cardiac arrests this could improve survival.

Recent studies suggest that atrial fibrillation (AF) burden (time AF is present) is an independent risk factor for stroke. The aim of this trial was to study the feasibility and accuracy to identify AF episodes and quantify AF burden

Respiration rate is an important physiological parameter whose abnormality has been regarded as an important indicator of various serious illnesses. Photoplethysmography (PPG) in wearable sensors potentially plays an important role in early disease detection by making respiration rate measurements

Comparison measured steps per minute determined by the Cardiowatch with steps per minute determined with the Actigraph CENTREPOINT Insight Watch. Single center prospective observational study collecting PPG and accelerometer data in a real world setting.

A total of 41 (19 female and 22 male) adults in good cardiovascular health (aged 19-79 years) continuously wore a smartwatch equipped with a PPG sensor and a 3D accelerometer (Cardio Watch 287, Corsano Health BV) for a period of 24 hours that represented their individual daily routine.

Regulations and standards put the emphasis on usability and human factor design in the development of medical device and risk management. This paper explains the main challenges for wearable devices by showing how usability and human

Screening for atrial fibrillation and timely initiation of oral anticoagulation, rhythm management, and treatment of concomitant cardiovascular conditions can improve outcomes in high-risk populations.

70 patients in an AF rhythm and 70 patients in sinus rhythm were recruited. Mean age was 73±12 (60% male) in the AF group, 59±20 in the sinus rhythm group (66% male). The BeatScanner app had a sensitivity of 89% (95% CI: 79-95%) and specificity of 67% (55- 78%).

Corsano’s sleep analysis is powered by Philips Wearable Sensing algorithms. This clinical trial is using wrist-worn PPG to analyze heart rate variability and an accelerometer to measure body movements, sleep stages and sleep statistics were automatically computed from overnight recordings.

The Army Combat Fitness Test (ACFT) is a performance assessment used by the U.S. Army to assess a cadet’s strength, endurance, and agility with a series of six events to ensure that cadets are combat ready.

Investigation of Corsano CardioWatch 287-2B devices for monitoring Elhers-Danlos Syndrome (EDS) patient physiology in both stable and symptomatic states for digital biomarker and personalized predictive model development

Investigation of Corsano CardioWatch 287-2B devices for monitoring and maintaining peak cognitive performance levels in healthy adults living in isolation to improve spaceflight readiness.

Improving health outcomes in areas such as early identification of infection, individual vaccine responses, and the monitoring of autoimmune conditions and immune-oncology therapies require medical approaches that transcend outdated, century-old practices for measuring inflammation, such as using fever as a primary indicator

The Corsano system for early Sepsis detection (CORSEP) trial. A collaborative trial between Universitätsmedizin Greifswald and Corsano Health B.V.

RR will be obtained by FDA cleared Reference Device General Electric® Carescape B850 cleared under K131414 with an oxygen mask Oxymask OM-1125-8 with an anesthesia gas sampling line of 2 m.

Out-of-hospital cardiac arrest (OHCA) is a leading cause of global mortality. Delays to initiation of cardiopulmonary resuscitation (CPR) should be as short as possible to achieve the highest survival chance.

Wearables have the potential to monitor patients remotely. The Corsano CardioWatch 287-2 is such a medical device that can monitor atrial fibrillation and long-term blood pressure.

MULTI-VITAL Multi Parameter Vital Signs Monitoring by the Corsano Cardiowatch 287-2 Validation Study

Investigating the potential of Corsano Cardiowatch 287 monitoring bracelet in monitoring patients with Chronic Obstructive Pulmonary Disease (COPD) at high risk of exacerbations

An observational study in patients between 12 and 70 years old with an acute asthma exacerbation, to determine the relation between phenotypical characteristics and the treatment response.

Evaluation of the performance and efficacy of the Corsano Cardiowatch 287 Bracelet in measuring respiratory rate at rest, as compared to golden standard and predicate device.

A phase I/II, multicenter study evaluating the feasibility, safety, and efficacy of point-of-care manufactured 19CP02 in subjects with relapsed/refractory B-cell non-Hodgkin lymphoma.

Evaluation of the performance of the Corsano Cardiowatch 287 Bracelet in identifying AF episodes and determining the AF burden in patients with known paroxysmal AF

The present study is looking for calibration and accuracy of SpO2, Pulse Rate and Respiration Rate derived by a newly developed based wrist device (CardioWatch 287-2 or Test Device).

The first 1000 days of life reflect the period from the 3 months before conception until the age of 2 years. An accumulating body of evidence suggest that social-demographic background

To study the feasibility, efficacy and performance of the Corsano CardioWatch 287 module with a photoplethysmographic sensor for measuring heart rate and RR-intervals

Vital sign changes often precede cardiac arrest, unexpected death, or ICU admission. If observed and treated, it could prevent the patient’s condition from deteriorating.

To demonstrate that patients with previously unknown atrial arrhythmias can be detected by a wearable in combination with Preventicus Heartbeats Core using a completely digital patient data capture system.

Obesity is a global epidemic. Obesity is associated with an increased risk of atrial fibrillation (AF). AF is the most common sustained cardiac rhythm disorder in humans with potentially life threatening complications.

Atrial fibrillation (AF) is the most common cardiac arrhythmia and a major risk factor for cerebrovascular insults. Screening for AF in hospitalized patients is challenging. The classical ECG monitoring requires

The number of cardiac patients with obesity is rising, however their number of referral to cardiac rehabilitation (CR) is not. Patients with obesity report a higher level of anxiety, a greater fear of movement after a cardiac event

In this study, we try to investigate the impact of air quality and green-blue spaces on vital signs, stress, and mood states. Using a scripted exposure protocol subjects will perform aerobic exercises

The first 1000 days of life reflect the period from the 3 months before conception until the age of 2 years. An accumulating body of evidence suggest that social-demographic background, lifestyle and nutrition of both parents during

In this prospective single-center trial, a wearable photoplethysmographic (PPG) sensor coupled with a cloud analytics service will be used to detect and quantify atrial fibrillation (AF) episodes in patients with known paroxysmal AF.

Patients with a suprasellar (hypothalamic) brain tumour often have excellent survival, but poor outcome due to hypothalamic dysfunction (HD). The hypothalamus is an endocrine gland and the key-regulator of our body.

Bone metastases represent a common complication in cancer patients, particularly in advanced stages of the disease. The presence of bone metastases can cause skeletal-related events, such as bone pain, pathological fractures

Dr. Eelko Ronner PhD presented study findings from a collaboration with Reinier de Graaf Hospital that found Cuffless NIBP resulted in accurate prediction of blood pressure based on an AI Pulse Wave Analysis model.

August 28, 2023, the Research Team of Reinier de Graaf Hospital presented results of the Corsano Cuffless Non-Invasive Blood Pressure at the ESC in Amsterdam.

Corsano Health is launching the company’s CardioWatch EU-MDR certified patient monitoring bracelet with Cuffless Non-Invasive Blood Pressure at ESC in Amsterdam…

Sepsis is a life-threatening emergency. Under the leadership of Dr. Matthias Gründling, SepsisDialog has been working on the early detection and treatment of sepsis for about 30 years.

Corsano’s CardioWatch EU-MDR certified patient monitoring bracelet will connect to cobas® pulse, Roche’s digitally enabled professional blood glucose management solution, combining multiple health applications in one device.

Corsano Health is launching the company’s second-generation EU-MDR wearable device that accurately measures eight vital parameters and makes raw PPG and ACC data available for further analysis by third party medical algorithm developers.

Revolutionizing the use of patient centric data in correlating effective clinical outcomes.

This technology should save thousands of lives: recognise cardiac arrests and sound an alarm. Corsano Health CardioWatch in Radboudumc Cardiac Arrest Clinical Trial.

As the benefits of remote patient monitoring (RPM) grow increasingly evident, wearable devices emerge as the revolutionary reformation of health assessment.

Corsano Health CardioWatch in Radboudumc Cardiac Arrest Clinical Trial Every year, approximately 17,000 Dutch people suffer a cardiac arrest outside the hospital. 7000 to 8000 this happens without someone being there to alert the emergency services. Radboudumc in Nijmegen and Corsano Health are now working on a special smartwatch.

Notified Body DARE!! Services B.V. declares that it has audited the quality assurance system in accordance with MDR Annex IX and that the relevant provisions of the Regulation 2017/745 dated May 5, 2017 concerning Medical Devices are fulfilled.

We are happy to announce that Corsano Health B.V. is medically certified complying with Annex IX (MDR) and EN-ISO 13485 standards.

The accuracy of Corsano CardioWatch 287 with pulse detection using photoplethysmography technology in cardiac patients was studied by S. Blok [1,2], M.A. Piek [1], I.I. Tulevski [1], G.A. Somsen [1], M.M. Winter [1,3]. In this single-centre prospective study, patients from an outpatient cardiology clinic underwent a simultaneous resting ECG and PPG recording.

High blood pressure (hypertension) is a common condition in which the long-term force of the blood against the artery walls is high enough that it will eventually cause heart disease with a patient population of 300m+ across the EU and US. Long-term high blood pressure is a major risk factor for stroke, coronary artery disease, heart...

Sepsis is a life-threatening condition characterized by a dysregulated immune response to infection, leading to organ dysfunction. It is considered a global health concern and a leading cause of death worldwide. Early detection and timely treatment are crucial for improving patient outcomes.

The most common cardiac arrhythmia is atrial fibrillation (AF). One in four will get it in the course of their life, the probability increases especially from the age of 65, as well as from 55 years with the presence of other risk factors (e.g. high blood pressure, diabetes, previous cardiovascular events) [1].

Telemetry rhythm surveillance is standard of care for a large subgroup of hospitalized cardiac patients. Indications for telemetry vary throughout spectra of risks, from direct detection of a life threatening arrhythmia, to determination of a rhythm or conduction disorder, to observation of heart frequency when tailoring treatment.

Corsano has medically certified it’s new software platform under ISO 13485 and EU-MDR. Latest technologies have been applied and the Software Development Process has been meticulously documented for CE-MDR and FDA Certification.

The ABPM scenario focuses on the impact of using one medical bracelet instead of the ABPM system, in the United States and Europe.

Corsano’s CardioWatch 287-2 is a transformative solution for hypertension monitoring, highlighting its potential to replace traditional 24-hour ABPM.

Atrial arrhythmias in older adults present significant healthcare challenges. This paper evaluates the efficacy of Corsano CardioWatch, a remote patient monitoring (RPM) tool, in detecting atrial fibrillation.

We are proud to announce that the Dutch Heart Foundation awarded Corsano Health a development project to recognize cardiac arrest and alert emergency services. Survival of Out-of-Hospital Cardiac Arrest (OHCA) depends on early recognition of Cardiac Arrest and initiation of Cardiopulmonary Resuscitation (CPR).